Pain · 2015 · 133 citations · 22 references
MedicinePharmacologyPharmacotherapyLocal AnesthesiaPain ManagementPain MedicineAnalgesiaNeuropathic PainNeuropathic Pain PharmacotherapyNociceptive PainPain MeasurementPain PhysiologyLidocaine TherapyNeuropathic Pain ReductionNeuropathic Pain ReliefPain HypersensitivityPain Intensity Rating ScalesPharmacological Pain ReliefTopical LidocaineVoltage-gated Sodium Channel Blockade
In neuropathic pain with irritable nociceptor (IN) phenotype, upregulation of sodium channels on nociceptors is supposed to be an important pain mechanism that may be targeted by topical sodium channel blockade. This randomised, double-blind, phenotype panel, crossover study with 4-week treatment periods of lidocaine 5% patch and placebo was performed to search for phenotype differences in effect. The primary efficacy measure was the total pain intensity on an 11-point numeric rating scale, and the primary objective was to compare the effect of lidocaine in patients with and without IN phenotype as defined by hypersensitivity and preserved small-fibre function determined by quantitative sensory testing. Forty-six patients with neuropathic pain due to nerve injury or postherpetic neuralgia were randomised. The modified intention-to-treat population comprised 15 patients with irritable nociceptor and 25 patients with nonirritable nociceptor. In the total sample, lidocaine reduced pain by 0.3 numeric rating scale points (95% confidence interval [CI]: 0.1-0.5) and pain-related sleep disturbance by 0.6 points (95% CI: 0.4-0.8) more than placebo (P = 0.007 and P < 0.001) and relieved pain by 0.4 verbal score (-1-5) points more (P = 0.036). For these measures, there was no significant interaction between treatment and phenotype, but there was a significant interaction for pain paroxysms (0.8, 95% CI: 0.4-1.2, P < 0.001) and deep aching pain (0.6, 95% CI: 0.1-1.0, P = 0.013). In conclusion, lidocaine 5% patch had an effect on peripheral neuropathic pain, and it may be most efficacious in patients with IN phenotype. The lack of significant phenotype differences may be caused by too low statistical power.
22
A new definition of neuropathic pain
Troels S. Jensen, Ralf Baron, Maija Haanpää et al. · Pain · 2011 · 1.4K citations
Medicine, Neurology, Neuroscience +11
Development and validation of the Neuropathic Pain Symptom Inventory
Didier Bouhassira, Nadine Attal, Jacques Fermanian et al. · Pain · 2004 · 1.3K citations
Medicine, Neurology, Pain Management +16